Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
July 11, 2024
Eva M. Geoghegan
Introduction: Ketamine has been shown to have rapid antidepressant effects. In addition, the use of EEG in depression offers a new approach to diagnose patients. It is necessary to understand locational-based EEG and MEG changes following ketamine in patients with depression to establish a potential biomarker panel. This study sought to identify consistent changes in band power as well as to...
Journal of Anesthesia and Translational Medicine
July 11, 2024
Kenji Hashimoto, Mingming Zhao, Tingting Zhu et al.
32 citations
Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, is similarly employed for anesthesia and analgesia. The anesthetic effects of both ketamine and esketamine arise from their antagonism of the N-methyl-D-aspartate receptor (NMDAR). In field of psychiatry, the rapid-acting antidepressant properties of ketamine for...
Quality in Sport
July 10, 2024
Patrycja Brzozowska, Klaudia Bulska, Konrad Sławek et al.
In spite of the variety of antidepressant drugs available for treating depressive disorder, treatment resistant depression (TRD) is still prevalent among the population. Despite being used mainly in anesthesia, and mostly phased out by more modern anesthetics, ketamine shows potential when it comes to depressive disorder treatment. We've set out to investigate the the relevant body of work to...
Indian Journal of Psychiatric Nursing
July 1, 2024
V. Ramasubramanian, S. Mathumathi, G. Thirumalaisamy et al.
ABSTRACT Depression is a common illness that affects about 3.8% of the population worldwide. Patients with major depression respond to antidepressant treatment, but 10%–20% of them do not improve or show a partial response. It is coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. Treatment-resistant...
Psychopharmacology
July 1, 2024
Nathaniel A. Shanok, Sabrina Muzac, Leah Brown et al.
7 citations
Major Depressive Disorder (MDD) is a pervasive psychiatric condition effecting approximately 21 million adults in the U.S. (8.4%). An estimated 30-60% of patients are resistant to traditional treatment approaches (medications and talk-therapy), alluding to the need for additional options. Two promising treatment modalities include transcranial magnetic stimulation (TMS) and ketamine infusions;...
Australian & New Zealand Journal of Psychiatry
July 1, 2024
Nicollette Lr Thornton, Dean J Wright, Nick Glozier
5 citations
One could argue that we are living through a period of innovation and change in psychiatry unlike that seen before, with repurposed medications emerging as novel treatments. However, despite evidence of enhanced clinical outcomes and potential medium-term savings, delivering these promising interventions is resource-intensive and perceived as difficult in the public sector. Consequently, they...
Journal of Affective Disorders
July 1, 2024
Ashok Seshadri, Larry J. Prokop, Balwinder Singh
50 citations
Intravenous (IV) racemic ketamine and intranasal (IN) esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression (TRD). This systematic review aims to evaluate the efficacy and safety of ketamine and esketamine at various dosages for depression. We included randomized controlled trials (RCTs) with parallel group dose comparison of ketamine and esketamine for...
Journal of Affective Disorders
July 1, 2024
Cameron N Calder, Angela T H Kwan, Kayla M Teopiz et al.
31 citations
Ketamine has been established as efficacious in adults living with Treatment-resistant Depression (TRD). Toward providing a quantifiable estimate of the clinical meaningfulness of the therapeutic benefit of ketamine, herein, we conduct a systematic review that aims to report the Number Needed to Treat (NNT) and the Number Needed to Harm (NNH). This systematic review searched Embase,...
Psychiatry Research
July 1, 2024
Ana Paula Anzolin, Daniel Prates Baldez, Bruno Braga Montezano et al.
2 citations
This investigation explores the efficacy of subcutaneous ketamine for mitigating depressive symptoms and suicidal ideation, addressing a crucial need for rapid-onset treatments in severe depression cases. It introduces an innovative approach to administering an NMDA receptor antagonist, significantly advancing psychopharmacological methods for treating suicidal behaviors as distinct entities,...
Biological Psychiatry Global Open Science
July 1, 2024
Julia Aepfelbacher, Benjamin Panny, Rebecca B Price
13 citations
Ketamine, an NMDA receptor antagonist, provides rapid antidepressant effects. Although much research has focused on neural and molecular mechanisms of action, it is critical to also consider psychological mechanisms that may contribute to its therapeutic efficacy. The construct of an awe-inducing experience, which is a well-validated psychological phenomenon tied to emotional well-being, had...